NCT01280695View on ClinicalTrials.gov

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo Capsules

DRUG

MSDC-0602 100 mg

MSDC-0602 100 mg Capsules

DRUG

MSDC-0602 250 mg

MSDC-0602 250 mg Capsules

DRUG

MSDC-0602 250 mg

MSDC-0602 500 mg Capsules

DRUG

Pioglitazone

Pioglitazone 45 mg Capsules

Trial Locations (14)

Unknown

Goodyear

Chula Vista

Los Angeles

Bradenton

Hialeah

Pembroke Pines

Chicago

Butte

Greensboro

Cincinnati

Charleston

Austin

San Antonio

Salt Lake City

Sponsors
All Listed Sponsors
lead

Metabolic Solutions Development Company

INDUSTRY

NCT01280695 - A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter